Franck Rouby

584 total citations
18 papers, 368 citations indexed

About

Franck Rouby is a scholar working on Oncology, Immunology and Infectious Diseases. According to data from OpenAlex, Franck Rouby has authored 18 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Immunology and 3 papers in Infectious Diseases. Recurrent topics in Franck Rouby's work include Cancer Immunotherapy and Biomarkers (6 papers), Drug-Induced Adverse Reactions (3 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). Franck Rouby is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Drug-Induced Adverse Reactions (3 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). Franck Rouby collaborates with scholars based in France, New Zealand and Switzerland. Franck Rouby's co-authors include Marion Sassier, Joëlle Micallef, Mathieu Puyade, M. Martin, Ghada Miremont‐Salamé, Marie‐Christine Pérault‐Pochat, Pierre Gillet, G. Weryha, Samy Babai and Nadine Petitpain and has published in prestigious journals such as Scientific Reports, Clinical Pharmacology & Therapeutics and Drug and Alcohol Dependence.

In The Last Decade

Franck Rouby

18 papers receiving 360 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Franck Rouby France 10 216 88 78 52 29 18 368
Baptiste Abbar France 10 291 1.3× 135 1.5× 58 0.7× 36 0.7× 27 0.9× 27 397
Sarah Yentz United States 10 255 1.2× 119 1.4× 50 0.6× 61 1.2× 33 1.1× 32 401
Shanthi Sivendran United States 11 167 0.8× 83 0.9× 40 0.5× 30 0.6× 32 1.1× 28 410
Yawei Wu China 5 212 1.0× 46 0.5× 60 0.8× 77 1.5× 49 1.7× 6 360
Élise Deluche France 16 357 1.7× 111 1.3× 33 0.4× 55 1.1× 71 2.4× 55 670
Marita Prohn United States 9 125 0.6× 46 0.5× 52 0.7× 26 0.5× 54 1.9× 16 311
Maya Gambarin‐Gelwan United States 10 271 1.3× 127 1.4× 52 0.7× 268 5.2× 27 0.9× 21 623
David T. Myers United States 6 68 0.3× 62 0.7× 94 1.2× 39 0.8× 22 0.8× 13 388
Smita Kayal India 11 197 0.9× 47 0.5× 40 0.5× 20 0.4× 51 1.8× 79 386
Taher Abu Hejleh United States 11 254 1.2× 158 1.8× 35 0.4× 52 1.0× 68 2.3× 45 445

Countries citing papers authored by Franck Rouby

Since Specialization
Citations

This map shows the geographic impact of Franck Rouby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franck Rouby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franck Rouby more than expected).

Fields of papers citing papers by Franck Rouby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franck Rouby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franck Rouby. The network helps show where Franck Rouby may publish in the future.

Co-authorship network of co-authors of Franck Rouby

This figure shows the co-authorship network connecting the top 25 collaborators of Franck Rouby. A scholar is included among the top collaborators of Franck Rouby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franck Rouby. Franck Rouby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Louis, Thomas, Joëlle Micallef, Renaud Sabatier, et al.. (2022). The safety and efficacy of palbociclib in older patients with advanced breast cancer in a real-world setting. Journal of Cancer Metastasis and Treatment. 8. 33–33. 5 indexed citations
2.
Martin, M., Johana Béné, Franck Rouby, et al.. (2022). Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database. Cancers. 14(20). 5030–5030. 9 indexed citations
3.
4.
Létinier, Louis, M. Benkebil, Franck Rouby, et al.. (2021). Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions. Clinical Pharmacology & Therapeutics. 110(2). 392–400. 22 indexed citations
5.
Favrelière, Sylvie, et al.. (2020). Drug‐induced hearing loss: a case/non‐case study in the French pharmacovigilance database. Fundamental and Clinical Pharmacology. 34(3). 397–407. 8 indexed citations
6.
Davion, Jean‐Baptiste, Bénédicte Lebrun‐Vignes, Fanny Rocher, et al.. (2020). Adalimumab and myositis: A case report and review of the French and international Pharmacovigilance Databases. Neuromuscular Disorders. 30(11). 915–920. 4 indexed citations
7.
Martin, M., Franck Rouby, Marion Sassier, et al.. (2020). Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. Journal for ImmunoTherapy of Cancer. 8(2). e001622–e001622. 84 indexed citations
8.
Rouby, Franck, Thierry Arnould, Pı̈erre Ambrosi, et al.. (2019). Un effet indésirable rare de l’amiodarone : la neuropathie optique. La Revue de Médecine Interne. 40(12). 826–830. 2 indexed citations
9.
Petitpain, Nadine, Franck Rouby, Marion Sassier, et al.. (2019). Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database. Scientific Reports. 9(1). 19419–19419. 52 indexed citations
10.
Cautela, Jennifer, Franck Rouby, Joe‐Elie Salem, et al.. (2019). Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event. Canadian Journal of Cardiology. 36(4). 476–481. 36 indexed citations
11.
Sabatier, Renaud, A.‐P. Jonville‐Béra, Anne Madroszyk, et al.. (2018). Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. Journal of Geriatric Oncology. 9(5). 494–500. 17 indexed citations
12.
Rouby, Franck, et al.. (2018). Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database. Therapies. 73(5). 385–388. 11 indexed citations
13.
Gauci, Marie-Léa, Philippe Boudou, Barouyr Baroudjian, et al.. (2018). Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study. Cancer Immunology Immunotherapy. 67(8). 1197–1208. 26 indexed citations
14.
Petitpain, Nadine, Franck Rouby, Marion Sassier, et al.. (2018). Thyroiditis and immune check point inhibitors: the post‐marketing experience using the French National Pharmacovigilance database. Fundamental and Clinical Pharmacology. 33(2). 241–249. 15 indexed citations
15.
Daviet, Florence, Franck Rouby, Pascale Poullin, et al.. (2018). Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. British Journal of Clinical Pharmacology. 85(2). 403–412. 41 indexed citations
16.
Pauly, Vanessa, Élisabeth Frauger, Vincent Pradel, et al.. (2010). Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse. Drug and Alcohol Dependence. 113(1). 29–36. 23 indexed citations
17.
Lamarque, Véronique, Louis Merle, Haleh Bagheri, et al.. (2008). Génériques et modalités de substituabilité : propositions de méthodes pour évaluer l’équivalence, la traçabilité et le relevé de Pharmacovigilance. Therapies. 63(4). 301–309. 3 indexed citations
18.
Lamarque, Véronique, Louis Merle, Haleh Bagheri, et al.. (2008). Generics and Substitution Modalities: Proposed Methods for the Evaluation of Equivalence, Traceability and Pharmacovigilance Reporting. Therapies. 63(4). 311–319. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Baptiste Abbar Breakdown of academic impact, for papers by Sarah Yentz Breakdown of academic impact, for papers by Shanthi Sivendran Breakdown of academic impact, for papers by Yawei Wu Breakdown of academic impact, for papers by Élise Deluche Breakdown of academic impact, for papers by Marita Prohn Breakdown of academic impact, for papers by Maya Gambarin‐Gelwan Breakdown of academic impact, for papers by David T. Myers Breakdown of academic impact, for papers by Smita Kayal Breakdown of academic impact, for papers by Taher Abu Hejleh
Rankless by CCL
2026